A new approach to choosing hormonal contraception through systematization of existing drugs


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To analyze the data available in the current literature on the most potential lines of development of contraceptives. To systematize approaches to choosing drugs and to appreciate the convenience of modern contraceptive decisions. Material and methods. The review includes the data of foreign and Russian articles published over 10 years and found in Pubmed on contraception, progestogens, and counseling, as well as statistical reports and data of marketing researches of contraception use in Russia. Results. The directions and ways of development of modern contraception since its emergence were described. The most potential components were assessed. A new grounded approach to forming a single range of contraceptives under a unified brand for the convenience of a physician is depicted. Conclusion. The convenience of collecting the verified ready contraceptive decisions for women with different needs has unquestionably a number of advantages and they are very convenient; time will show whether this will improve the quality of contraceptive use, its duration, and the whole situation.

Full Text

Restricted Access

About the authors

Aleksandr L. Tikhomirov

A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia

Email: tikhomiroval@yandex.ru
MD, PhD, Professor of Faculty of Medicine Obstetrics and Gynecology Department

Igor B. Manukhin

A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia

MD, PhD, Professor, Head of Faculty of Medicine Obstetrics and Gynecology Department

Mariyana A. Gevorkyan

A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia

Email: marianagevorkyan@mail.ru
MD, PhD, Professor of Faculty of Medicine Obstetrics and Gynecology Department

Ekaterina I. Manukhina

A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia

Email: katemanu@mail.ru
MD, PhD, Professor of Faculty of Medicine Obstetrics and Gynecology Department

Viktor V. Kazenashev

A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia

Email: vkazenashev@mail.ru
MD, PhD, Assistant of Faculty of Medicine Obstetrics and Gynecology Department

References

  1. World Contraceptive Use 2003. United Nations Department of Economic and Social Affairs Population Division.
  2. Статистическая информация Минздрава России. Available at: https:// www.rosminzdrav.ru/ministry/61/22/stranitsa-979/statisticheskaya-informatsi-ya-minzdrava-rossii [Statistical information of Ministry of Health of Russia. Available at: https://www.rosminzdrav.ru/ministry/61/22/stranitsa-979/statis-ticheskaya-informatsiya-minzdrava-rossii (in Russian)]
  3. Прилепская В.Н., ред. Руководство по контрацепции. М.: МЕДпресс-информ; 2010. 448с. [Prilepskaya V.N., ed. Contraceptive Guide. Moscow: MEDpress-inform; 2010. 448p. (in Russian)]
  4. Armstrong C. ACOG Guidelines on noncontraceptive uses of hormonal contraceptives. Am. Fam. Physician. 2010; 82(3): 288-95.
  5. Wiegratz I., Kuhl H. Metabolic and clinical effects of progestogens. Eur. J. Contracept. Reprod. Health Care. 2006; 11(3): 153-61.
  6. Blanc A.K., Curtis S., Croft T. Does contraceptive discontinuation matter? Quality of care and fertility consequences. MEASURE Evaluation Technical Report Series No. 3. Carolina Population Center, University of North Carolina at Chapel Hill; 1999.
  7. Volumetric concept test. Ipsos, 2014.
  8. Usage & Attitude, GFK, 2012.
  9. Akerlund M., Rede A., Westergaard J. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol. Br. J. Obstet. Gynaecol. 1993; 100(9): 832-8.
  10. Endrikat J.S., Milchev N.P., Kapamadzija A., Georgievska J., Gerlinger C., Schmidt W., Feroze S. Bleeding pattern, tolerance and patient satisfaction with a drospirenone-containing oral contraceptive evaluated in 3488 women in Europe, the Middle East and Canada. Contraception. 2009; 79(6): 428-32.
  11. Дубровина С.О. Синдром поликистозных яичников: современный обзор. Гинекология. 2016; 18(5): 14-9. [Dubrovina S.O. Polycystic ovary syndrome: modern review. Ginekologiya. 2016; 18(5): 14-9. (in Russian)]
  12. Ткаченко Л.В., Свиридова Н.И. Гиперпластические процессы эндометрия в пременопаузе: современные возможности гормональной коррекции и профилактики. Гинекология. 2013; 15(2): 8-12. [Tkachenko L.V., Sviridova N.I. Endometrial hyperplasia in premenopausal women: modern possibilities of hormonal correction and prevention. Ginekologiya. 2013; 15(2): 8-12. (in Russian)]
  13. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas. 2008; 61(1-2): 151-7.
  14. Lopez L.M., Kaptein A.A., Helmerhorst F.M. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst. Rev. 2012; (2): CD006586.
  15. Lucky A.W., Koltun W., Thiboutot D., Niknian M., Sampson-Landers C., Korner P., Marr J. A combined oral contraceptive containing 3-mg drospirenone/ 20-microg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment. Cutis. 2008; 82(2): 143-50.
  16. Niemeier V., Kupfer J., Gieler U. Acne vulgaris--psychosomatic aspects. J. Dtsch. Dermatol. Ges. 2006; 4(12): 1027-36.
  17. Jones-Caballero M., Chren M.M., Soler B., Pedrosa E., Peñas P.F. Quality of life in mild to moderate acne: relationship to clinical severity and factors influencing change with treatment. J. Eur. Acad. Dermatol. Venereol. 2007; 21(2): 219-26.
  18. Aydinlik S., Kaufmann J., Lachnit-Fixson U., Lehnert J. Long-term therapy of signs of androgenisation with a low-dosed antiandrogen-oestrogen combination. Clin. Trials J. 1990; 27(6): 392-402.
  19. Национальные медицинские критерии приемлемости методов контрацепции. М.; 2012. [National medical eligibility criteria of contraceptive methods. Moscow; 2012. (in Russian)]
  20. WHO. Medical eligibility criteria for contraceptive use. 5th ed. 2015. 267p.
  21. Здравоохранение в России 2015. Статистический сборник/Росстат. М.; 2015. 174с.
  22. Korver T. et al. A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 micrograms/day or levonorgestrel 30 micrograms/day. Collaborative Study Group on the Desogestrel-containing Progestogen-only Pill. Eur. J. Contracept. Reprod. Health Care. 1998; 3(4): 169-78.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies